Abstract 3710
Background
In the ALTER0203 trial (NCT02449343), anlotinib hydrochloride was used as subsequence therapy for adult advanced soft tissue sacorma (STS) pts who progressed after prior systemic therapies. It has demonstrated that anlotinib significantly prolonged PFS in advanced STS with multiple pathological subgroups. There’s rare treatment method for alveolar soft part sarcoma (ASPS) due to chemotherapy insensitive. Here we report the efficacy of anlotinib on ASPS in 1st line or ≥ 2nd line.
Methods
233 pts were randomised in a 2:1 ratio to receive anlotinib (12 mg QD from day 1 to 14 of a 21-day cycle) or placebo till progression or intolerable toxicity. ASPS pts could be treated at 1st line without prior systemic therapies. Primary endpoint is progression-free survival (PFS). Data cutoff by 2017.4.30, follow-up is still ongoing.
Results
Median PFS of ASPS (n = 56) was significantly improved in the anlotinib arm (n = 38) compared with placebo arm (n = 18) (18.23 vs. 3.00 months, p < 0.0001), and the most common grade ≥3 treatment-related AEs were hypertension, γ-glutamyltransferase increased, hand-foot syndrome and hypertriglyceridemia. Furthermore, remarkable advantages in PFS were observed in the anlotinib arm as well regardless of the treatment line. Meanwhile, the DCR in anlotinib arm was also significantly increased compared to the placebo arm. (Data presented in the table)Table:
1694P Efficacy (date is immature)
1st line | ≥2nd line | |||||||
---|---|---|---|---|---|---|---|---|
Anlotinib (n = 18) | Placebo (n = 10) | HR | p-vaule | Anlotinib (n = 20) | Placebo (n = 8) | HR | P-vaule | |
Events/ Censored (n/n) | 6/12 | 5/5 | 5/15 | 6/2 | ||||
mPFS (mos) | 15.4 | 3.00 | 0.24 | 0.0073 | NR | 1.50 | 0.14 | <0.0001 |
ORR(%) | 22.22 | 0.00 | 0.2652 | 25.00 | 0.00 | 0.2808 | ||
DCR(%) | 83.33 | 40.00 | 0.0346 | 90.00 | 37.50 | 0.0095 |
Conclusions
In the ALTER0203 trial, a significant improvement in PFS was found in anlotinib treated ASPS from both subgroups (1st line or ≥ 2nd line treatment). This is indicating that anlotinib could be an appropriate option for ASPS pts regardless of the treatment line.
Clinical trial identification
NCT02449343.
Editorial acknowledgement
Legal entity responsible for the study
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Funding
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4325 - Multiple synchronous mechanisms may contribute to osimertinib resistance in non-small cell lung cancer (NSCLC) patients: insights of the MATCH-R study
Presenter: Diego Enrico
Session: Poster Display session 1
Resources:
Abstract
2185 - Sequential treatment with afatinib followed by 3rd generation EGFR-TKI – subgroup analysis of the GIDEON trial: a prospective non-interventional study (NIS) in EGFR mutated NSCLC patients in Germany
Presenter: Wolfgang Brückl
Session: Poster Display session 1
Resources:
Abstract
1524 - Effectiveness of sequencing TKIs in patients with EGFR mutation-positive Non-small-Cell Lung Cancer (NSCLC): A French National medico administrative claim database analysis
Presenter: Nicolas Girard
Session: Poster Display session 1
Resources:
Abstract
5733 - Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)
Presenter: Tae Min Kim
Session: Poster Display session 1
Resources:
Abstract
5440 - Different stories for different EGFR exon 19 deletion variants
Presenter: Chao Zhao
Session: Poster Display session 1
Resources:
Abstract
2982 - Safety and activity of alflutinib in patients with advanced EGFR T790M mutation non-small cell lung cancer who progressed after EGFR-TKI therapy
Presenter: Yuan-Kai Shi
Session: Poster Display session 1
Resources:
Abstract
4002 - Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm+) advanced NSCLC: updated data from the GioTag real-world study
Presenter: Maximilian Hochmair
Session: Poster Display session 1
Resources:
Abstract
2941 - Treatment patterns of EGFR mt+ NSCLC IV pts: Real world data of the NOWEL network
Presenter: Julia Roeper
Session: Poster Display session 1
Resources:
Abstract
4154 - TP53 mutations predicts worse prognosis in EGFR-mutated NSCLC patients receiving TKIs in first- or further line of treatment
Presenter: Matteo Canale
Session: Poster Display session 1
Resources:
Abstract
1175 - HER3 ligand heregulin expression and clinical implication in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
Presenter: Kimio Yonesaka
Session: Poster Display session 1
Resources:
Abstract